{
    "additionDate": "2021-01-18T07:41:41Z",
    "biotoolsCURIE": "biotools:tide",
    "biotoolsID": "tide",
    "confidence_flag": "tool",
    "credit": [
        {
            "email": "zhangjing@tongji.edu.cn",
            "name": "Jing Zhang",
            "typeEntity": "Person"
        },
        {
            "email": "peng.jiang@nih.gov",
            "name": "Peng Jiang",
            "orcidid": "https://orcid.org/0000-0002-7828-5486",
            "typeEntity": "Person"
        },
        {
            "email": "xsliu@ds.dfci.harvard.edu",
            "name": "X. Shirley Liu",
            "typeEntity": "Person"
        }
    ],
    "description": "Large-scale public data reuse to model immunotherapy response and resistance.\n\nTumor Immune Dysfunction and Exclusion (TIDE).\n\nWe validated TIDE performance on predicting anti-PD1 and anti-CTLA4 response across several melanoma datasets and a limited dataset of non-small cell lung cancer (NSCLC). TIDE may not work on cancer types other than melanoma and NSCLC (e.g., glioblastoma, or renal cell carcinoma) and therapies other than anti-PD1 and anti-CTLA4 (e.g., anti-PDL1, or Car T).",
    "editPermission": {
        "type": "private"
    },
    "function": [
        {
            "operation": [
                {
                    "term": "Expression analysis",
                    "uri": "http://edamontology.org/operation_2495"
                },
                {
                    "term": "Standardisation and normalisation",
                    "uri": "http://edamontology.org/operation_3435"
                }
            ]
        }
    ],
    "homepage": "http://tide.dfci.harvard.edu",
    "lastUpdate": "2021-02-27T09:33:32Z",
    "name": "TIDE",
    "owner": "zsmag19",
    "publication": [
        {
            "doi": "10.1186/S13073-020-0721-Z",
            "metadata": {
                "abstract": "\u00a9 2020 The Author(s).Despite growing numbers of immune checkpoint blockade (ICB) trials with available omics data, it remains challenging to evaluate the robustness of ICB response and immune evasion mechanisms comprehensively. To address these challenges, we integrated large-scale omics data and biomarkers on published ICB trials, non-immunotherapy tumor profiles, and CRISPR screens on a web platform TIDE (http://tide.dfci.harvard.edu). We processed the omics data for over 33K samples in 188 tumor cohorts from public databases, 998 tumors from 12 ICB clinical studies, and eight CRISPR screens that identified gene modulators of the anticancer immune response. Integrating these data on the TIDE web platform with three interactive analysis modules, we demonstrate the utility of public data reuse in hypothesis generation, biomarker optimization, and patient stratification.",
                "authors": [
                    {
                        "name": "Fu J."
                    },
                    {
                        "name": "Li K."
                    },
                    {
                        "name": "Zhang W."
                    },
                    {
                        "name": "Wan C."
                    },
                    {
                        "name": "Zhang J."
                    },
                    {
                        "name": "Jiang P."
                    },
                    {
                        "name": "Liu X.S."
                    }
                ],
                "citationCount": 32,
                "date": "2020-02-26T00:00:00Z",
                "journal": "Genome Medicine",
                "title": "Large-scale public data reuse to model immunotherapy response and resistance"
            },
            "pmcid": "PMC7045518",
            "pmid": "32102694"
        }
    ],
    "topic": [
        {
            "term": "Biomarkers",
            "uri": "http://edamontology.org/topic_3360"
        },
        {
            "term": "Oncology",
            "uri": "http://edamontology.org/topic_2640"
        },
        {
            "term": "RNA-Seq",
            "uri": "http://edamontology.org/topic_3170"
        },
        {
            "term": "Preclinical and clinical studies",
            "uri": "http://edamontology.org/topic_3379"
        },
        {
            "term": "Gene expression",
            "uri": "http://edamontology.org/topic_0203"
        }
    ]
}